Meclizine – Possibly the most gatekept growth plate modulator?

oska_blnn

oska_blnn

Bronze
Joined
Oct 28, 2024
Posts
370
Reputation
244
I am genuinely surprised that almost nobody here has ever brought up Meclizine in the context of skeletal growth. The entire community seems focused on GH, IGF-1, CNP analogues, and other well-known interventions, yet Meclizine appears to have slipped completely under the radar.



Mechanistically, it is fascinating. Meclizine is an old antihistamine prescribed for motion sickness, but beyond its H1 receptor blockade, it has a very specific off-target effect: it downregulates FGFR3 signaling in growth plate chondrocytes. For context, FGFR3 is the single most important negative regulator of longitudinal bone growth. High FGFR3 activity suppresses chondrocyte proliferation and hypertrophy, thereby reducing the efficiency of endochondral ossification.



By attenuating FGFR3, Meclizine essentially removes part of the “brake” on the growth plate. The implications:

• Wider proliferative zones in the physis.
• Greater hypertrophic chondrocyte size.
• Increased longitudinal growth velocity while the plates remain open.



Crucially, this has nothing to do with accelerating epiphyseal closure. That process is primarily driven by estrogen exposure and senescence within the growth plate, not FGFR3 signaling. In other words, Meclizine cannot extend the lifespan of the growth plate, but it can plausibly increase the amount of growth achieved during its remaining lifespan.



Animal models support this: in achondroplasia mouse studies, Meclizine treatment partially rescued longitudinal bone growth by counteracting overactive FGFR3. Yet, for some reason, this compound remains almost entirely unmentioned in discussions on height optimization.



I cannot help but feel that Meclizine is one of the most gatekept drugs in this space. Readily available, mechanistically sound, supported by preclinical data — yet absent from virtually every conversation. Perhaps I am among the very few drawing attention to it here, but it seems to me like an overlooked key in the growth optimization puzzle.



Has anyone else seriously considered or experimented with this? I would be very interested to hear perspectives and reasons why it’s not as good as i’m saying it is.

Chatgpt wrote it for me cuz ion wanna write but trust me y’all meclizine is fucking op :lul: please bump.
 
Last edited:
  • +1
Reactions: currycel67, cookedcel, afkaik and 9 others
Sort by date Sort by votes
gpt
 
  • +1
Reactions: aids and Wexilarious
Upvote 0 Downvote
  • +1
  • JFL
Reactions: currycel67, Sadist, aids and 2 others
Upvote 0 Downvote
oska_blnn said:
I am genuinely surprised that almost nobody here has ever brought up Meclizine in the context of skeletal growth. The entire community seems focused on GH, IGF-1, CNP analogues, and other well-known interventions, yet Meclizine appears to have slipped completely under the radar.



Mechanistically, it is fascinating. Meclizine is an old antihistamine prescribed for motion sickness, but beyond its H1 receptor blockade, it has a very specific off-target effect: it downregulates FGFR3 signaling in growth plate chondrocytes. For context, FGFR3 is the single most important negative regulator of longitudinal bone growth. High FGFR3 activity suppresses chondrocyte proliferation and hypertrophy, thereby reducing the efficiency of endochondral ossification.



By attenuating FGFR3, Meclizine essentially removes part of the “brake” on the growth plate. The implications:

• Wider proliferative zones in the physis.
• Greater hypertrophic chondrocyte size.
• Increased longitudinal growth velocity while the plates remain open.



Crucially, this has nothing to do with accelerating epiphyseal closure. That process is primarily driven by estrogen exposure and senescence within the growth plate, not FGFR3 signaling. In other words, Meclizine cannot extend the lifespan of the growth plate, but it can plausibly increase the amount of growth achieved during its remaining lifespan.



Animal models support this: in achondroplasia mouse studies, Meclizine treatment partially rescued longitudinal bone growth by counteracting overactive FGFR3. Yet, for some reason, this compound remains almost entirely unmentioned in discussions on height optimization.



I cannot help but feel that Meclizine is one of the most gatekept drugs in this space. Readily available, mechanistically sound, supported by preclinical data — yet absent from virtually every conversation. Perhaps I am among the very few drawing attention to it here, but it seems to me like an overlooked key in the growth optimization puzzle.



Has anyone else seriously considered or experimented with this? I would be very interested to hear perspectives and reasons why it’s not as good as i’m saying it is.

Chatgpt wrote it for me cuz ion wanna write but trust me y’all meclizine is fucking op :lul: please bump.
Click to expand...
the only question is does it work with normalactive fgfr3
 
Upvote 0 Downvote
oska_blnn said:
I am genuinely surprised that almost nobody here has ever brought up Meclizine in the context of skeletal growth. The entire community seems focused on GH, IGF-1, CNP analogues, and other well-known interventions, yet Meclizine appears to have slipped completely under the radar.



Mechanistically, it is fascinating. Meclizine is an old antihistamine prescribed for motion sickness, but beyond its H1 receptor blockade, it has a very specific off-target effect: it downregulates FGFR3 signaling in growth plate chondrocytes. For context, FGFR3 is the single most important negative regulator of longitudinal bone growth. High FGFR3 activity suppresses chondrocyte proliferation and hypertrophy, thereby reducing the efficiency of endochondral ossification.



By attenuating FGFR3, Meclizine essentially removes part of the “brake” on the growth plate. The implications:

• Wider proliferative zones in the physis.
• Greater hypertrophic chondrocyte size.
• Increased longitudinal growth velocity while the plates remain open.



Crucially, this has nothing to do with accelerating epiphyseal closure. That process is primarily driven by estrogen exposure and senescence within the growth plate, not FGFR3 signaling. In other words, Meclizine cannot extend the lifespan of the growth plate, but it can plausibly increase the amount of growth achieved during its remaining lifespan.



Animal models support this: in achondroplasia mouse studies, Meclizine treatment partially rescued longitudinal bone growth by counteracting overactive FGFR3. Yet, for some reason, this compound remains almost entirely unmentioned in discussions on height optimization.



I cannot help but feel that Meclizine is one of the most gatekept drugs in this space. Readily available, mechanistically sound, supported by preclinical data — yet absent from virtually every conversation. Perhaps I am among the very few drawing attention to it here, but it seems to me like an overlooked key in the growth optimization puzzle.



Has anyone else seriously considered or experimented with this? I would be very interested to hear perspectives and reasons why it’s not as good as i’m saying it is.

Chatgpt wrote it for me cuz ion wanna write but trust me y’all meclizine is fucking op :lul: please bump.
Click to expand...
Link me some of the studies proving ur point
@MyDreamIsToBe183CM
 
  • +1
Reactions: Sadist
Upvote 0 Downvote
oska_blnn said:
I am genuinely surprised that almost nobody here has ever brought up Meclizine in the context of skeletal growth. The entire community seems focused on GH, IGF-1, CNP analogues, and other well-known interventions, yet Meclizine appears to have slipped completely under the radar.



Mechanistically, it is fascinating. Meclizine is an old antihistamine prescribed for motion sickness, but beyond its H1 receptor blockade, it has a very specific off-target effect: it downregulates FGFR3 signaling in growth plate chondrocytes. For context, FGFR3 is the single most important negative regulator of longitudinal bone growth. High FGFR3 activity suppresses chondrocyte proliferation and hypertrophy, thereby reducing the efficiency of endochondral ossification.



By attenuating FGFR3, Meclizine essentially removes part of the “brake” on the growth plate. The implications:

• Wider proliferative zones in the physis.
• Greater hypertrophic chondrocyte size.
• Increased longitudinal growth velocity while the plates remain open.



Crucially, this has nothing to do with accelerating epiphyseal closure. That process is primarily driven by estrogen exposure and senescence within the growth plate, not FGFR3 signaling. In other words, Meclizine cannot extend the lifespan of the growth plate, but it can plausibly increase the amount of growth achieved during its remaining lifespan.



Animal models support this: in achondroplasia mouse studies, Meclizine treatment partially rescued longitudinal bone growth by counteracting overactive FGFR3. Yet, for some reason, this compound remains almost entirely unmentioned in discussions on height optimization.



I cannot help but feel that Meclizine is one of the most gatekept drugs in this space. Readily available, mechanistically sound, supported by preclinical data — yet absent from virtually every conversation. Perhaps I am among the very few drawing attention to it here, but it seems to me like an overlooked key in the growth optimization puzzle.



Has anyone else seriously considered or experimented with this? I would be very interested to hear perspectives and reasons why it’s not as good as i’m saying it is.

Chatgpt wrote it for me cuz ion wanna write but trust me y’all meclizine is fucking op :lul: please bump.
Click to expand...
Gray, Meclizine is an h1 receptor blockade, it has passive fgfr3 down regulations, guess when is fgfr3 high, pre pubertal u dumbfuh, dont js copy shi.
 
Upvote 0 Downvote
Last edited:
  • +1
Reactions: Org3cel
Upvote 0 Downvote
read this study, it seems promising, maybe run this with a pth analog since it looks like it might mess up bone mineral density

Clinical dosage of meclozine promotes longitudinal bone growth, bone volume, and trabecular bone quality in transgenic mice with achondroplasia - PMC

Achondroplasia (ACH) is the most common short-limbed skeletal dysplasia caused by gain-of-function mutations in the fibroblast growth factor receptor 3 (FGFR3). No effective FGFR3-targeted therapies for ACH are currently available. By drug ...
pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
 
  • +1
Reactions: jeoyw9192
Upvote 0 Downvote
Upvote 0 Downvote
kenalodaunt said:
not yet but luckily its an OTC medication so if you want to abuse it you could just walk into a pharmacy
Click to expand...
Seems promising tbh I'll research it a bit more and look around for more anecdotes
 
  • +1
Reactions: kenalodaunt
Upvote 0 Downvote
oska_blnn said:
I am genuinely surprised that almost nobody here has ever brought up Meclizine in the context of skeletal growth. The entire community seems focused on GH, IGF-1, CNP analogues, and other well-known interventions, yet Meclizine appears to have slipped completely under the radar.



Mechanistically, it is fascinating. Meclizine is an old antihistamine prescribed for motion sickness, but beyond its H1 receptor blockade, it has a very specific off-target effect: it downregulates FGFR3 signaling in growth plate chondrocytes. For context, FGFR3 is the single most important negative regulator of longitudinal bone growth. High FGFR3 activity suppresses chondrocyte proliferation and hypertrophy, thereby reducing the efficiency of endochondral ossification.



By attenuating FGFR3, Meclizine essentially removes part of the “brake” on the growth plate. The implications:

• Wider proliferative zones in the physis.
• Greater hypertrophic chondrocyte size.
• Increased longitudinal growth velocity while the plates remain open.



Crucially, this has nothing to do with accelerating epiphyseal closure. That process is primarily driven by estrogen exposure and senescence within the growth plate, not FGFR3 signaling. In other words, Meclizine cannot extend the lifespan of the growth plate, but it can plausibly increase the amount of growth achieved during its remaining lifespan.



Animal models support this: in achondroplasia mouse studies, Meclizine treatment partially rescued longitudinal bone growth by counteracting overactive FGFR3. Yet, for some reason, this compound remains almost entirely unmentioned in discussions on height optimization.



I cannot help but feel that Meclizine is one of the most gatekept drugs in this space. Readily available, mechanistically sound, supported by preclinical data — yet absent from virtually every conversation. Perhaps I am among the very few drawing attention to it here, but it seems to me like an overlooked key in the growth optimization puzzle.



Has anyone else seriously considered or experimented with this? I would be very interested to hear perspectives and reasons why it’s not as good as i’m saying it is.

Chatgpt wrote it for me cuz ion wanna write but trust me y’all meclizine is fucking op :lul: please bump.
Click to expand...
btw y’all i’ll start using this soon, my paycheck arrived at the 15 of this month, i’ll let y’all know on any side effects once i start.
 
  • +1
Reactions: Jacklinks29 and rizzyjizzy720
Upvote 0 Downvote
kenalodaunt said:
i measured my height at 5'10" (which is .5 inches taller) but i'm not sure if it's just because of morning height, i'll make sure and let you know
Click to expand...
Nigga thinks it's possible he grew .5 inches in a day :lul:
 
  • JFL
Reactions: Abdullahm06, cadee and Asoka
Upvote 0 Downvote
its a weak inhibitor it wont do shit jfl
 
Upvote 0 Downvote
I’m a gray but doesn’t overreactive fgfr3 make shorter bones also 95% of mice experiments doesn’t apply to humans. Normal puberty growth is driven by GH, IGF-1, testosterone, and nutrition not FGFR3. The last also is fgfr3 is only tested on mice with a rare fgfr3 problem
 
Upvote 0 Downvote
rizzyjizzy720 said:
I’m a gray but doesn’t overreactive fgfr3 make shorter bones also 95% of mice experiments doesn’t apply to humans. Normal puberty growth is driven by GH, IGF-1, testosterone, and nutrition not FGFR3. The last also is fgfr3 is only tested on mice with a rare fgfr3 problem
Click to expand...
humans with overactive fgfr3 ended up being shorter
 
Upvote 0 Downvote
You must log in or register to reply here.

Similar threads

choppedcel2
  • Question
Meclizine, Cope?
Replies
3
Views
86
fletcherp
fletcherp
nunu7
  • Question
Discussion HGH + AI + FGFR3 Inhibitor Stack
Replies
15
Views
267
exyonf
exyonf
the big L
  • Question
Guide THE ULTIMATE HEIGHTMAXING STACK (Credits to Noahmon)
Replies
13
Views
640
Squeakswashere
Squeakswashere
JOTAROSON
The fGFR3 gene and its inhibitors((The deformity gene)
Replies
10
Views
128
vi24v_
vi24v_
M
  • Question
Discussion Nintedanib as Infigratinib replacement for FGFR3 block in heightmaxxing
Replies
3
Views
213
Zorbital
Z

Users who are viewing this thread

  • Total: 3 (Looksmaxers: 1, Bluepillers: 2)
    Back
    Top